Pharma Mar
PharmaMar SA is a Spanish biopharmaceutical enterprise focused on discovering, developing, and commercializing marine-derived oncology drugs. The company develops antitumor therapies including Yondelis (trabectedin) for soft tissue sarcoma and Zepzelca (lurbinectedin) for small cell lung cancer, alongside marine biotechnology applications. Principal revenues derive from commercial prescription drug sales, international licensing royalty fees, upfront partnership payments, and active pharmaceutical ingredient supply. Core end markets encompass medical oncology clinics, hospital networks, specialty prescription patients, and global pharmaceutical distribution partners across Europe, the US, and Asia-Pacific. PharmaMar holds a market-leading global position in marine-derived biopharmaceutical drug discovery and targeted oncology therapeutics. The corporation is headquartered in Colmenar Viejo, Spain, and its shares trade on the Mercado Continuo of the Spanish stock exchanges.
3 of the funds FundTelligence covers report a position in Pharma Mar.
- Legal name
- PHARMA MAR SA
- Sector
- Health Care
- Country
- Spain
- Funds holding it
- 3
Funds holding Pharma Mar
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.1 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)